STAT+: Amylyx nears pivotal endocrine drug study readout

Summary

Amylyx Pharmaceuticals is preparing to announce results from a pivotal study evaluating a new treatment for a rare endocrine disorder. The readout represents a significant milestone for the company and patients with this condition.